Albumedix strikes first deal as stand-alone unit
Danish-based biotech group Albumedix has made its first move on the M&A scene since its separation from enzymes maker Novozymes and is buying a number of assets from a US-based firm.
BY STEFAN SINGH KAILAY
Albumedix has already begun making moves in terms of M&A just two weeks after Novozymes founded the company by spinning off its biopharma activities.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novozymes separates biopharma business
For abonnenter
Chairman of new Novozymes company: We might need funding
For abonnenter
